ArticleWorld journal of surgical oncology2026
A logNII-based model for predicting pathological complete response following neoadjuvant therapy in esophageal squamous cell carcinoma: a retrospective single-center study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aimed to develop and validate a predictive model for pathological complete response (pCR) following neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC), focusing on Nutrition-Inflammation Index (NII) and its potential nonlinear relationship with pCR.
methodsA single-center retrospective cohort of 363 ESCC patients receiving neoadjuvant therapy followed by esophagectomy was analyzed. We employed restricted cubic splines within multivariable logistic regression to characterize the relationship between log-transformed Nutrition-Inflammation Index (logNII) and pCR. The model's performance was rigorously assessed by its discriminative ability (Area Under the Curve, AUC), calibration, and clinical utility using bootstrap validation and decision curve analysis (DCA).
resultsThe logNII demonstrated a significant, independent, and nonlinear association with pCR after adjusting for key clinical covariates. The final predictive model, which incorporated logNII and clinical variables, achieved an AUC of 0.816 (95% CI: 0.770-0.863). DCA confirmed the model provided significant net clinical benefit across a wide range of threshold probabilities, highlighting its potential for clinical decision-making.
conclusionWe established logNII as a robust, independent, and nonlinear predictor of pCR in ESCC. The developed model demonstrates excellent predictive performance and clinical utility, offering a valuable tool for personalizing treatment strategies in the neoadjuvant setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.